CTOs on the Move

Kansas City University College of Dental Medicin

www.kcumb.edu

 
Kansas City University announced June 4 its plans to open a College of Dental Medicine on its Joplin, Missouri, campus, with an anticipated groundbreaking in 2020. The goal is to seat a class of 80 students in 2022.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.kcumb.edu
  • 1750 Independence Ave.
    Kansas City, AB USA 64106
  • Phone: 800.234.4847

Executives

Name Title Contact Details

Funding

Kansas City University College of Dental Medicine raised $30M on 11/04/2019

Similar Companies

480 Biomedical

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.

Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

BioShield Technologies

BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mo Bio Labs

Mo Bio Labs is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue Biopharma

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.